F2G Ltd., a UK-based antifungal drug discovery and development company, has appointed Ralf Schmid chief financial officer. Schmid carries 20 years’ experience to F2G and joins the company from Nabriva Therapeutics AG, where he was chief financial officer and chief operating officer. He also held senior positions in finance and administration at various multinational companies including Sandoz.
-
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
Recent moves in the industry include changes at the top at iOnctura
and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.